These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21417957)

  • 21. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
    Phillips W; Schaefer S
    Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with statins: who benefits?
    Singh A; Davidson M
    Endocrinol Metab Clin North Am; 2014 Dec; 43(4):993-1006. PubMed ID: 25432393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
    Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
    Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colesevelam hydrochloride in the management of dyslipidemia.
    Armani A; Toth PP
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
    Agouridis AP; Filippatos TD; Tsimihodimos V; Elisaf MS
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):355-66. PubMed ID: 21438815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy for the treatment of dyslipidemia.
    Streja D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    Guyton JR
    Curr Opin Lipidol; 2010 Aug; 21(4):372-7. PubMed ID: 20625257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.